Nucletron BV has signed an agreement with BSD Medical Corporation (USA) in which Nucletron has become exclusive worldwide sales agent for BSD Medical Corporation's new generation of systems for interstitial hyperthermia therapy.
"Interstitial hyperthermia is an interesting complimentary treatment modality to brachytherapy. A combination with interstitial hyperthermia could increase the tumor sensitivity and contribute to significantly better clinical results" said Rudolf L. Scholte President & CEO of Nucletron B.V..
Hyrum A. Mead, President of BSD Medical Corporation said, "Nucletron and BSD Medical have much in common because the combined use of brachytherapy (by Nucletron) and microwave hyperthermia (by BSD Medical) in the treatment of cancer can substantially improve results in cancer treatment. It is a winning combination for both our patients and our respective companies."
Interstitial Hyperthermia complements brachytherapy, employing the same catheters used to perform the HDR treatment as a passage for tiny microwave antennae. These antennae provide hyperthermia therapy. Hyperthermia sensitizes the tumor to radiation treatment and can improve significantly the outcome for the patient. Therefore the combination of the two techniques in one treatment step will be a significant step forward.